Key statistics
On Wednesday, Scisparc Ltd (SPRC:NAQ) closed at 0.613, 5.00% above its 52-week low of 0.5838, set on Feb 05, 2026.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 0.6611 |
|---|---|
| High | 0.6611 |
| Low | 0.5933 |
| Bid | 0.6252 |
| Offer | 0.71 |
| Previous close | 0.661 |
| Average volume | 204.84k |
|---|---|
| Shares outstanding | 4.35m |
| Free float | 3.05m |
| P/E (TTM) | -- |
| Market cap | 2.88m USD |
| EPS (TTM) | -- |
Data delayed at least 15 minutes, as of Feb 11 2026 21:00 GMT.
More ▼
Announcements
- SciSparc: NeuroThera Labs Granted U.S. Patent for Cannabinoid Technology to Overcome Antimicrobial Resistance such as MRSA
- SciSparc Successfully Completes Acquisition of IP Portfolio, Advances Toward Immediate Commercialization
- SciSparc Signs Definitive Agreement to Acquire a Treasury of Patents for the Endoscope Market- Entering Multi-Billion Dollar Opportunity
- SciSparc Announces Receipt of Nasdaq Notification of Minimum Stockholders’ Equity Non-Compliance
- SciSparc: Neurothera Labs Granted Patent by Israeli Patent Office for its Proprietary Opioid-Based Patent Family to Enhance Pain Relief and Reduce Side Effects
- SciSparc: Neurothera Labs Signs Non-Binding Term Sheet to Acquire Majority Stake in a Quantum Algorithm Bio Data Analysis Company
- SciSparc Plans on Entering the Multi-Billion-Dollar GERD Device Market with Acquisition of an Approved IP Portfolio
- SciSparc to Acquire Treasury of Patents for Innovative Medical Endoscopy Systems
- SciSparc: Neurothera Labs Announces Israeli Patent Application in Collaboration with Clearmind Medicine for Novel Non-Hallucinogenic Neuroplastogen Treatment for Depression
- SciSparc Announces Closing of the Acquisition of a Publicly Traded Company on the TSXV to which it transferred its Advanced Clinical Stage Pharmaceutical Portfolio
More ▼
